SSA
IGMS

Schonfeld Strategic Advisors’s IGM Biosciences IGMS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,500
Closed -$308K – 2744
2022
Q1 		$308K Buy
+11,500
New +$214K ﹤0.01% 1681
2021
Q2 		– Sell
-18,921
Closed -$1.45M – 2106
2021
Q1 		$1.45M Buy
+18,921
New +$1.72M 0.02% 762
2020
Q1 		– Sell
-12,000
Closed -$458K – 1316
2019
Q4 		$458K Buy
+12,000
New +$301K 0.01% 778

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schonfeld Strategic Advisors's IGMS Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 11,500 shares — an estimated $308K sold.

Schonfeld Strategic Advisors first reported a position in IGMS in Q4 2019 and held it in 3 quarters. The position peaked at $1.45M in Q1 2021. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

  • Schonfeld Strategic Advisors reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,500 IGM Biosciences shares in Q2 2022, an estimated $308K.
  • Schonfeld Strategic Advisors first reported a position in IGM Biosciences in Q4 2019 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's IGM Biosciences position peaked at $1.45M in Q1 2021.
  • 89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.